Inversago is a clinical stage biopharmaceutical company dedicated to developing therapies for patients suffering from debilitating metabolic diseases. A privately-owned company with a unique portfolio of peripherally-acting CB1 receptor (CB1r) blockers, the company completed a Series C funding in 2022 led by New Enterprise Associates (“NEA”).
Our main investors
For more information on investment opportunities, please contact us at: firstname.lastname@example.org.
Inversago Pharma benefits from the financial support of the Ministère de l’Économie et de l’Innovation du Québec